Study of quality of life in chronic Spontaneous Urticaria patients and treated by omalizumab (Xolair®)

Registry ID

EUCTR2014-005424-97

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

NOVARTIS PHARMA SAS

Start date

2015-01-12

Completion date

2016-01-11

Last update

2026-08-16

Conditions

• chronic spontaneous urticaria

Summary

Evaluate the proportion of patients achieving disease control (urticaria control test [UCT] score of greater than or equal to 12) at Week 12 in adult patients with CSU with inadequate response to H1 antihistamine treatment and treated by omalizumab 300 mg S.C. every 4 weeks

Locations

• , , France

Related clinical trials

• Tildrakizumab, an Anti-IL-23 Antibody for the Treatment of Refractory Chronic Spontaneous Urticaria – a single-arm, open-label, phase II study (TAILOR-CSU)

View on source registry